Day Three

Sunday, 10 December

Below is a summary of the session timetable for Day Three. Greater detail for each session, including speakers and presentation titles, is given further down the page.

Biomedical meeting Clinical meeting
Session 9A: Neuroinflammation and Glial Signalling Session 9B: Correlates of Clinical Progression
Session 10A: Integrated Omics and Pathway Analysis Session 10B: Cognitive Change
   
Session 11: Joint Closing Session
Biomedical MeetingClinical meetingJoint session
Session 9A: 08.30 - 10.00
NEUROINFLAMMATION AND GLIAL SIGNALLING
08.30 – 09.00 Imaging glial activation in people with ALS N Atassi (USA)
09.00 – 09.20 MicroRNAs secreted by C9orf72 patient-derived astrocytes contribute to impairment in axonal growth and cell death in vitro L Ferraiuolo (UK)
09.20 – 09.40 Slowing disease progression in the SOD1 mouse model of ALS by blocking neuregulin-induced microglial activation F Song (USA)
09.40 – 10.00 The role of microglia in TDP-43 clearance and redistribution in the zebrafish spinal cord M Morsch (Australia)
Session 10A: 10.30 - 12.30
INTEGRATED OMICS AND PATHWAY ANALYSIS
10.30 – 11.00 Analyzing biological networks to identify novel disease pathways E Fraenkel (USA)
11.00 – 11.30 Early analysis of clinical and iPS motor neuron multi-omics signature from a large population of sporadic and familial ALS patients reveals verifiable subgroups and molecular pathways J Rothstein (USA)
11.30 – 11.50 Molecular phenotyping of human neurons with TDP-43 pathology reveals derepression of transposable elements E Lee (USA)
11.50 – 12.10 Extensive RNA sequencing study in brain tissue obtained from patients harbouring a C9ORF72 repeat expansion M van Blitterswijk (USA)
12.10 – 12.30 Integrated molecular landscape of ALS provides insights into disease etiology G Poelmans (Netherlands)
Session 9B: 08.30 - 10.00
CORRELATES OF CLINICAL PROGRESSION
08.30 – 08.50 Hypermetabolism is associated with lower motor neurone burden, functional decline and predicts survival in ALS F Steyn (Australia)
08.50 – 09.10 Lipid metabolism and survival across the ALS-FTD spectrum R Ahmed (Australia)
09.10 – 09.30 Clinical characteristics and associated factors in ALS patients with longer survival Q Wei (China)
09.30 – 09.45 Biomarker mixtures predict ALSFRS-R at time of diagnosis P Factor-Litvak (USA)
09.45 – 10.00 Blood vitamin D levels correlate with ALS severity: A prospective study N Pageot (France)
Session 10B: 10.30 - 12.40
COGNITIVE CHANGE
10.30 – 11.00 The ALS-FTD continuum C Lomen-Hoerth (USA)
11.00 – 11.20 A population-based study of cognition in the ALS-FTDS: The incidence and nature of language changes M Pinto-Grau (Ireland)
11.20 – 11.40 Language is the cognitive function which is most vulnerable to change in ALS D Lulé (Germany)
11.40 – 12.00 Behavioural changes in bvFTD and ALS-FTD: A prospective study J Saxon (UK)
12.00 – 12.20 Longitudinal assessment in ALS using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) B Poletti (Italy)
12.20 – 12.40 Development and clinical implications of the brief Dimensional Apathy Scale (b-DAS) R Radakovic (UK)
Session 11: 14.00 - 15.15
14.00 – 14.30 ALS: Lessons from SOD1 and prospects for SOD1 and C9orf72 gene silencing R Brown (USA)
14.30 - 14.40 Patient Impact Award
14.40 – 14.50 Invitation to Glasgow 2018
14.50 – 15.15 Late breaking news
Day 1 Programme

Day One

Friday, 8 December

Day 2 Programme

Day Two

Saturday, 9 December

Day 3 Programme

Day Three

Sunday, 10 December